Health Catalyst (HCAT) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Health Catalyst (NASDAQ: HCAT):

• 8/11/2025 – Health Catalyst had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $6.00. They now have an “overweight” rating on the stock.
• 8/8/2025 – Health Catalyst was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $3.50 price target on the stock, down previously from $6.50.
• 8/8/2025 – Health Catalyst had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock, down previously from $9.00.
• 8/8/2025 – Health Catalyst had its price target lowered by analysts at Stifel Nicolaus from $5.50 to $4.50. They now have a “hold” rating on the stock.
• 7/9/2025 – Health Catalyst had its price target lowered by analysts at Evercore ISI from $5.00 to $4.00. They now have an “in-line” rating on the stock.

Health Catalyst Trading Down 0.3%

HCAT opened at $2.92 on Monday. Health Catalyst, Inc. has a one year low of $2.52 and a one year high of $9.24. The stock has a market capitalization of $205.48 million, a PE ratio of -1.93 and a beta of 1.46. The business’s 50 day moving average price is $3.74 and its 200 day moving average price is $4.15. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently bought and sold shares of HCAT. First Light Asset Management LLC increased its position in shares of Health Catalyst by 99.1% during the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company’s stock worth $47,279,000 after purchasing an additional 5,195,686 shares in the last quarter. Nepsis Inc. increased its position in shares of Health Catalyst by 2,072.1% during the first quarter. Nepsis Inc. now owns 2,090,812 shares of the company’s stock worth $9,471,000 after purchasing an additional 1,994,555 shares in the last quarter. Whetstone Capital Advisors LLC acquired a new stake in shares of Health Catalyst during the first quarter worth about $7,724,000. Alyeska Investment Group L.P. increased its position in shares of Health Catalyst by 74.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after purchasing an additional 861,150 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Health Catalyst during the first quarter worth about $2,674,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.